GI Cancer
Advertisement
For postoperative morbidity and mortality, surgery alone had the highest probability rate.
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
While biliary tract cancer is one of the fastest-growing types of early-onset cancers, little is known about its biology.
Little is known about the details of genomic differences and clinical implications between patients with GISTs.
The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.
Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
FLOT and nivo seems to be associated with improved efficacy, whereas chemo followed by IO therapy is insufficient.
The LEAP-012 study showed improved progression-free survival with lenvatinib, pembrolizumab, and TACE in HCC.
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Combining encorafenib and cetuximab with FOLFIRI chemotherapy showed strong antitumor activity in BRAF V600E-mutant mCRC.
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.